Is Bevacizumab Alone Effective in Newly Diagnosed Glioblastoma?

A study in the United Kingdom investigated whether bevacizumab, known to work in recurrent glioblastoma, is also effective alone in newly diagnosed disease. It found no effect in these patients.
Glioblastoma is the most common and most aggressive brain tumor. It takes its name from the glial cells (brain support cells) where it originates, beginning when they become abnormal for an unknown reason. Despite recent treatment advances, prognosis remains poor, with average survival approximately 14 months. The first treatment step is surgical removal of as much tumor as possible, followed by temozolomide chemotherapy with concurrent radiotherapy. If disease progresses or recurs despite these treatments, bevacizumab is used in an effort to prolong survival.
Bevacizumab is antiangiogenic: it blocks angiogenesis, cancer cells' formation of new vessels, an important factor in cancer development and progression. It is known to work in advanced or recurrent glioblastoma. A recent study examined whether it is also effective alone in newly diagnosed cases.
The study involved 637 newly diagnosed patients divided into 2 groups. One received bevacizumab while the other did not. After approximately 20 months' follow-up, no significant difference in survival or disease course was found.
In conclusion, concurrent temozolomide and radiotherapy have prolonged survival and marked important recent progress, but survival remains short. New strategies are therefore needed, and this research contributes usefully. Every method cannot succeed; finding no effect or difference can also be important because such studies guide future research. For now, bevacizumab alone will continue to be used only in advanced and recurrent glioblastoma. Discovering effects in other patient profiles and beginning its use there is certainly possible in the future.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.